Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from <scp>BOIN12</scp> ‐ <scp>PFS</scp> : A Bayesian Optimal Interval Phase <scp>I</scp> / <scp>II</scp> Design Incorporating Progression‐Free Survival Endpoint. Local targets link to admitted publications; unresolved targets remain external evidence.
Novel Clinical Trial Designs With Dose Optimization to Improve Long‐Term Outcomes
10.1158/1078-0432.ccr-23-2222 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Dose‐Finding Based on Efficacy‐Toxicity Trade‐Offs
10.1111/j.0006-341x.2004.00218.x · 2004 · External reference
An Adaptive Dose‐Finding Method Using a Change‐Point Model for Molecularly Targeted Agents in Phase I Trials
10.1002/sim.6981 · 2016 · External reference
BOIN‐ET: Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes
10.1002/pst.1864 · 2018 · External reference
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility‐Based Dose Finding in Immunotherapy and Targeted Therapies
10.1200/po.20.00257 · 2020 · External reference
A Utility‐Based Bayesian Optimal Interval (U‐BOIN) Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies
10.1002/sim.8361 · 2019 · External reference
Using Data Augmentation to Facilitate Conduct of Phase I‐II Clinical Trials With Delayed Outcomes
10.1080/01621459.2014.881740 · 2014 · External reference
TITE‐BOIN‐ET: Time‐To‐Event Bayesian Optimal Interval Design to Accelerate Dose‐Finding Based on Both Efficacy and Toxicity Outcomes
10.1002/pst.1995 · 2020 · External reference
TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose With Late‐Onset Toxicity and Efficacy
10.1002/sim.9337 · 2022 · External reference
Regulatory and Clinical Consequences of Negative Confirmatory Trials of Accelerated Approval Cancer Drugs: Retrospective Observational Study
10.1136/bmj.n1959 · 2021 · External reference
Validating ORR and PFS as Surrogate Endpoints in Phase II and III Clinical Trials for NSCLC Patients: Difference Exists in the Strength of Surrogacy in Various Trial Settings
10.1186/s12885-022-10046-z · 2022 · External reference
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta‐analysis
10.1001/jamaoncol.2017.5236 · 2018 · External reference
SPIRIT: A Seamless Phase I/II Randomized Design for Immunotherapy Trials
10.1002/pst.1869 · 2018 · External reference
A Utility‐Based Bayesian Phase I–II Design for Immunotherapy Trials With Progression‐Free Survival End Point
10.1111/rssc.12288 · 2019 · External reference
BIPSE: A Biomarker‐Based Phase I/II Design for Immunotherapy Trials With Progression‐Free Survival Endpoint
10.1002/sim.9265 · 2022 · External reference
Generalized Phase I‐II Designs to Increase Long Term Therapeutic Success Rate
10.1002/pst.2301 · 2023 · External reference
Monitoring Event Times in Early Phase Clinical Trials: Some Practical Issues
10.1191/1740774505cn121oa · 2005 · External reference
Bayesian Optimal Phase II Clinical Trial Design With Time‐To‐Event Endpoint
10.1002/pst.2030 · 2020 · External reference
Time‐To‐Event Model‐Assisted Designs for Dose‐Finding Trials With Delayed Toxicity
10.1093/biostatistics/kxz007 · 2020 · External reference
Bayesian Optimal Interval Designs for Phase I Clinical Trials
10.1111/rssc.12089 · 2015 · External reference
Randomized Phase II Trial of FOLFIRI‐Panitumumab Compared With FOLFIRI Alone in Patients With RAS Wild‐Type Circulating Tumor DNA Metastatic Colorectal Cancer Beyond Progression to First‐Line FOLFOX‐Panitumumab: The BEYOND Study (GEMCAD 17‐01)
10.1007/s12094-022-02868-x · 2022 · External reference
Unresolved reference
1972 · External reference
